NO20013064D0 - Kombinasjonsterapi med bestråling og en cox-2-inhibitor ved behandling av neoplasia - Google Patents

Kombinasjonsterapi med bestråling og en cox-2-inhibitor ved behandling av neoplasia

Info

Publication number
NO20013064D0
NO20013064D0 NO20013064A NO20013064A NO20013064D0 NO 20013064 D0 NO20013064 D0 NO 20013064D0 NO 20013064 A NO20013064 A NO 20013064A NO 20013064 A NO20013064 A NO 20013064A NO 20013064 D0 NO20013064 D0 NO 20013064D0
Authority
NO
Norway
Prior art keywords
inhibitor
radiation
neoplasia
cox
treatment
Prior art date
Application number
NO20013064A
Other languages
English (en)
Other versions
NO20013064L (no
Inventor
John P Mckearn
Jaime L Masferrer
Luka Milas
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of NO20013064D0 publication Critical patent/NO20013064D0/no
Publication of NO20013064L publication Critical patent/NO20013064L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Radiation-Therapy Devices (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
NO20013064A 1998-12-23 2001-06-20 Kombinasjonsterapi med bestraling og en cox-2-inhibitor ved behandling av neoplasia NO20013064L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11378698P 1998-12-23 1998-12-23
US09/385,214 US6649645B1 (en) 1998-12-23 1999-08-27 Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
PCT/US1999/030669 WO2000038716A1 (en) 1998-12-23 1999-12-22 Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia

Publications (2)

Publication Number Publication Date
NO20013064D0 true NO20013064D0 (no) 2001-06-20
NO20013064L NO20013064L (no) 2001-08-23

Family

ID=26811473

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013064A NO20013064L (no) 1998-12-23 2001-06-20 Kombinasjonsterapi med bestraling og en cox-2-inhibitor ved behandling av neoplasia

Country Status (19)

Country Link
US (3) US6649645B1 (no)
EP (2) EP1522313A1 (no)
JP (1) JP2002535249A (no)
KR (1) KR100705744B1 (no)
AT (1) ATE281845T1 (no)
AU (1) AU769665B2 (no)
BR (1) BR9916544A (no)
CA (1) CA2356547A1 (no)
CY (1) CY1105584T1 (no)
DE (1) DE69921852T2 (no)
DK (1) DK1140181T3 (no)
EA (1) EA200100571A1 (no)
ES (1) ES2232205T3 (no)
HU (1) HUP0104669A3 (no)
IL (2) IL143805A0 (no)
NO (1) NO20013064L (no)
PL (1) PL349149A1 (no)
PT (1) PT1140181E (no)
WO (1) WO2000038716A1 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
WO2001097806A1 (en) * 2000-06-20 2001-12-27 Herbst Arthur L Cox-2 inhibitors and the prevention of the side effects of radiation therapy
US20040033938A1 (en) * 2000-09-12 2004-02-19 Britten Nancy J. Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
FR2820636B1 (fr) * 2001-02-09 2007-10-05 Laprophan Laboratoires De Prod Utilisation de l'indometacine calcique pour traiter les pathologies a mediation de la cyclo-oxygenase 2
US20030153801A1 (en) * 2001-05-29 2003-08-14 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease
AU2003217697A1 (en) * 2002-02-25 2003-09-09 University Of Rochester Medical Center Prevention of and therapy for radiation toxicity of normal tissues using drugs which block il-1 activity
US20080153894A1 (en) * 2002-12-19 2008-06-26 Pharmacia Corporation Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
CN1747950A (zh) 2002-12-19 2006-03-15 美国辉瑞有限公司 用于治疗眼病的作为蛋白激酶抑制剂的2－(1h－吲唑－6－基氨基)－苯甲酰胺化合物
US7259266B2 (en) * 2003-03-31 2007-08-21 Pharmacia Corporation Benzopyran compounds useful for treating inflammatory conditions
DE602004017479D1 (de) 2003-08-29 2008-12-11 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
US20080199484A1 (en) * 2003-10-06 2008-08-21 Cedars-Sinai Medical Center Use Of Cox-2 Inhibitor to Prevent T-Cell Anergy Induced By Dendritic Cell Therapy
WO2006023332A2 (en) * 2004-08-20 2006-03-02 Children's Medical Center Corporation Method for the inhibition of angiogenesis or cancer using protective antigen related molecules
PL1786785T3 (pl) 2004-08-26 2010-08-31 Pfizer Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
WO2006040676A1 (en) * 2004-10-12 2006-04-20 Pharmacia & Upjohn Company Llc Nitrosated benzopyran compounds as novel cyclooxygenase-2 selective inhibitors
WO2006096778A2 (en) * 2005-03-08 2006-09-14 Mitsui Norin Co., Ltd Polyphenol coxib combinations and methods
MX2010000465A (es) * 2007-07-12 2010-08-30 Tragara Pharmaceuticals Inc Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
US20120015919A1 (en) * 2007-09-24 2012-01-19 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and aromatase inhibitors or combinations of cox-2 inhibitors and estrogen receptor antagonists
CA2700673A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
JP2010540459A (ja) * 2007-09-24 2010-12-24 トラガラ ファーマシューティカルズ，インク． Ｃｏｘ‐２阻害薬及びｅｇｆｒ［ｅｒｂｂ１］とｈｅｒ‐２［ｅｒｂｂ２］の二重阻害薬を用いた癌を治療するための併用療法
JP2011506277A (ja) * 2007-11-28 2011-03-03 トラガラ ファーマシューティカルズ，インク． Ｃｏｘ−２阻害薬と代謝拮抗物質との組み合わせを使用する癌治療
US20110086850A1 (en) * 2008-04-11 2011-04-14 Board Of Regents, The University Of Texas System Radiosensitization of tumors with indazolpyrrolotriazines for radiotherapy
US8002838B2 (en) * 2008-06-11 2011-08-23 Depuy Products, Inc. Joint prosthesis with positionable head
CN104876937B (zh) 2010-02-12 2017-07-28 辉瑞公司 8‑氟‑2‑{4‑[(甲氨基)甲基]苯基}‑1,3,4,5‑四氢‑6H‑氮杂*并[5,4,3‑cd]吲哚‑6‑酮的马来酸盐、其药物组合物及其用途
TWI646091B (zh) 2012-12-28 2019-01-01 日商衛斯克慧特股份有限公司 鹽類及晶形
PL3050878T3 (pl) 2013-09-24 2022-01-24 Fujifilm Corporation Zawierający atom azotu związek lub jego sól, lub ich kompleks z metalem
JP6621477B2 (ja) 2014-12-18 2019-12-18 ファイザー・インク ピリミジンおよびトリアジン誘導体ならびにａｘｌ阻害薬としてのそれらの使用

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3840597A (en) 1971-02-24 1974-10-08 Riker Laboratories Inc Substituted 2-phenoxy alkane-sulfonanilides
DE2756113A1 (de) 1977-12-16 1979-06-21 Thomae Gmbh Dr K Neue 4-hydroxy-2h-1,2-benzothiazin- 3-carboxamid-1,1-dioxide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
FR2465486A1 (fr) 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
DE3121153A1 (de) 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
US5663180A (en) 1983-10-29 1997-09-02 G.D. Searle & Co. Substituted cyclopentenes for the treatment of inflammation
US4659695A (en) 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
US4760053A (en) 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4775660A (en) 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
JPH0753725B2 (ja) * 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
US5047554A (en) 1989-04-18 1991-09-10 Pfizer Inc. 3-substituted-2-oxindole derivatives
US5616458A (en) 1990-03-14 1997-04-01 Board Of Regents, University Of Tx System Tripterygium wilfordii hook F extracts and components, and uses thereof
JPH0766587B2 (ja) 1990-10-20 1995-07-19 エルジー電子株式会社 Ｖｃｒの予約録画方法
US5324720A (en) 1992-03-20 1994-06-28 Merck & Co., Inc. Methods of achieving antitumor activity using 16-membered-macrolide-type compounds
AU5292193A (en) * 1992-10-02 1994-04-26 Merck & Co., Inc. N-(mercaptoacyl)peptidyl derivatives as antidegenerative agents
ATE135697T1 (de) 1992-10-28 1996-04-15 Shionogi & Co Benzylidenderivate
WO1994012169A1 (en) * 1992-11-25 1994-06-09 Merck & Co., Inc. Carboxy-peptidyl derivatives as antidegenerative active agents
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5543297A (en) 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
CA2297592A1 (en) 1993-01-15 1994-07-21 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US6274590B1 (en) 1993-01-15 2001-08-14 G. D. Searle & Co. Method of treating skin related conditions
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
WO1994026731A1 (en) 1993-05-13 1994-11-24 Merck Frosst Canada Inc. 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
GB9602877D0 (en) 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5434178A (en) 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
CN1061036C (zh) 1993-11-30 2001-01-24 G·D·瑟尔公司 用于治疗炎症的取代的吡唑基苯磺酰胺类化合物
US5451589A (en) 1993-12-21 1995-09-19 Eli Lilly And Company Methods of inhibiting ovarian dysgenesis, delayed puberty, or sexual infantilism
US5393790A (en) 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5418254A (en) 1994-05-04 1995-05-23 G. D. Searle & Co. Substituted cyclopentadienyl compounds for the treatment of inflammation
AU2424895A (en) 1994-05-04 1995-11-29 G.D. Searle & Co. Substituted spirodienes for the treatment of inflammation
US5486534A (en) 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
JPH10504542A (ja) 1994-07-27 1998-05-06 ジー．ディー．サール アンド カンパニー 炎症処置用の置換チアゾール化合物
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5420343A (en) 1994-08-31 1995-05-30 G. D. Searle & Co. Derivatives of aromatic cyclic alkylethers
US5547975A (en) 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US5696143A (en) 1994-09-20 1997-12-09 Talley; John J. Benz G! indazolyl derivatives for the treatment of inflammation
GB2294879A (en) 1994-10-19 1996-05-15 Merck & Co Inc Cylcooxygenase-2 Inhibitors
AU688980B2 (en) 1994-10-27 1998-03-19 Merck Frosst Company Stilbene derivatives useful as cyclooxygenase-2 inhibitors
US5908852A (en) 1994-11-14 1999-06-01 G. D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5739166A (en) 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5596008A (en) 1995-02-10 1997-01-21 G. D. Searle & Co. 3,4-Diaryl substituted pyridines for the treatment of inflammation
US5686470A (en) 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
DK0809636T3 (da) 1995-02-13 2003-01-06 Searle & Co Substituerede isoxazoler til behandling af inflammation
US5691374A (en) 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
WO1996038418A1 (en) 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
JPH0977664A (ja) * 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
US5789413A (en) 1996-02-01 1998-08-04 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
US5733909A (en) 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
CA2249009C (en) 1996-04-12 2003-09-16 G.D. Searle & Co. Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
US5922742A (en) 1996-04-23 1999-07-13 Merck Frosst Canada Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
KR100205229B1 (ko) 1996-05-15 1999-07-01 윤종용 태양전지 전원장치
US5883267A (en) 1996-05-31 1999-03-16 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
US5863946A (en) 1996-06-06 1999-01-26 Abbott Laboratories Iminoxyderivatives of fenamates as inhibitors of prostaglandin biosynthesis
GB9615867D0 (en) 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
US5677318A (en) 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5776967A (en) 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
FR2751964B1 (fr) 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives diarylmethylene carbocycliques, leurs procedes de preparation, et leurs utilisations en therapeutique
FR2751966B1 (fr) * 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique
US5830911A (en) 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
JP2001503395A (ja) * 1996-10-15 2001-03-13 ジー．ディー．サール アンド カンパニー 腫瘍新生の処置および予防にシクロオキシゲナーゼ―２阻害剤を使用する方法
US5681842A (en) 1996-11-08 1997-10-28 Abbott Laboratories Prostaglandin synthase-2 inhibitors
US5869524A (en) 1996-11-12 1999-02-09 American Home Products Corporation Indene inhibitors of COX-2
JPH10158234A (ja) * 1996-12-02 1998-06-16 Kotobuki Seiyaku Kk ２−フェニルアズレン誘導体及びその製造方法
WO1998025896A1 (en) 1996-12-10 1998-06-18 G.D. Searle & Co. Substituted pyrrolyl compounds for the treatment of inflammation
ATA16597A (de) * 1997-02-03 1998-04-15 Nycomed Austria Gmbh Neue substituierte p-sulfonylaminobenzol- sulfonsäureamide
US5783597A (en) 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
US5811425A (en) 1997-03-04 1998-09-22 Abbott Laboratories Heterocyclic compounds as COX-2 inhibitors
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
FR2769311B1 (fr) 1997-10-07 1999-12-24 Union Pharma Scient Appl Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique
US5972986A (en) 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
NZ333399A (en) * 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
US6277878B1 (en) 1998-09-07 2001-08-21 Pfizer Inc Substituted indole compounds as anti-inflammatory and analgesic agents

Also Published As

Publication number Publication date
NO20013064L (no) 2001-08-23
PL349149A1 (en) 2002-07-01
CY1105584T1 (el) 2010-07-28
ES2232205T3 (es) 2005-05-16
HUP0104669A2 (hu) 2002-05-29
CA2356547A1 (en) 2000-07-06
DE69921852D1 (de) 2004-12-16
EP1522313A1 (en) 2005-04-13
PT1140181E (pt) 2005-02-28
AU2713400A (en) 2000-07-31
DE69921852T2 (de) 2005-10-27
ATE281845T1 (de) 2004-11-15
EA200100571A1 (ru) 2001-12-24
JP2002535249A (ja) 2002-10-22
IL143805A (en) 2007-03-08
HUP0104669A3 (en) 2002-08-28
US20040053935A1 (en) 2004-03-18
DK1140181T3 (da) 2005-02-14
BR9916544A (pt) 2002-01-08
EP1140181A1 (en) 2001-10-10
EP1140181B1 (en) 2004-11-10
IL143805A0 (en) 2002-04-21
US20040053934A1 (en) 2004-03-18
WO2000038716A1 (en) 2000-07-06
US6649645B1 (en) 2003-11-18
WO2000038716A9 (en) 2000-11-30
KR100705744B1 (ko) 2007-04-11
KR20010109273A (ko) 2001-12-08
AU769665B2 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
NO20013064D0 (no) Kombinasjonsterapi med bestråling og en cox-2-inhibitor ved behandling av neoplasia
IL143870A0 (en) Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
NO991381D0 (no) Kombinasjonsterapi for behandling av psykoser
NO971015L (no) Forbindelser og metoder for behandling av cancer
EA200300953A1 (ru) Терапевтические комбинации для применения при сердечно-сосудистых и воспалительных заболеваниях
EA200301104A1 (ru) Антиангиогенная комбинированная терапия для лечения онкологических заболеваний
DK0739212T3 (da) Anvendelse af interleukin-12 til forebyggelse af transplantat-vs.-værtssygdom
WO2003026643A3 (en) Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
NO20005885L (no) Kombinasjonsterapi for behandling av refraktær depresjon
ATE377429T1 (de) Anwendung von pdt zur inhibierung von hyperplasie der intima
DE69910425D1 (de) Neue therapeutische verwendung von nicergoline
NO20010390L (no) Behandling av angstsykdommer
IS6707A (is) Efnablanda til forvarna og meðhöndlunar á krabbameini
BR0317491A (pt) Método de usar um inibidor de cox-2 e um inibidor de topoisomerase ii como uma terapia de combinação no tratamento de neoplasia
UA22007A (uk) Спосіб лікуваhhя хроhічhого hеспецифічhого простатиту

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application